Why GSK (GSK) is a Top Momentum Stock for the Long-Term
https://www.zacks.com/stock/news/2224825/why-gsk-gsk-is-a-top-momentum-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2224825
Feb 12, 2024 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
0
Top Analyst Reports for Microsoft, Exxon Mobil & Toyota Motor
https://www.zacks.com/commentary/2223276/top-analyst-reports-for-microsoft-exxon-mobil-toyota-motor?cid=CS-ZC-FT-research_daily-2223276
Feb 08, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Exxon Mobil Corporation (XOM) and Toyota Motor Corporation (TM).
0
GSK shares trading in green for seventh consecutive session
https://seekingalpha.com/news/4064082-gsk-shares-trading-in-green-for-seventh-consecutive-session?source=feed_sector_healthcare
Feb 07, 2024 - GSK PLC (GSK) shares continue to rise, up 0.49% at $41.96.
0
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
https://www.zacks.com/stock/news/2218970/gsk-lags-q4-earnings-tops-sales-issues-upbeat-24-guidance?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218970
Jan 31, 2024 - GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.
0
GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost
https://www.cnbc.com/2024/01/31/gsk-posts-blowout-rsv-vaccine-sales-raises-outlook.html
Jan 31, 2024 - The RSV shot, called Arexvy, booked £1.2 billion, or $1.5 billion, in sales after only being on the market for roughly half a year.
0
GSK Q4 to spotlight vaccine business amid Arexvy rollout
https://seekingalpha.com/news/4060182-gsk-q4-spotlight-vaccine-business-amid-arexvy-rollout?source=feed_sector_healthcare
Jan 30, 2024 - GSK's (GSK) Q4 2023 results are exected to highlight its vaccine division amid the ongoing early market rollout of its RSV vaccine, Arexvy. Read more here.
0
GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?
https://www.zacks.com/stock/news/2217328/gsk-gears-up-for-q4-earnings-will-it-surpass-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2217328
Jan 29, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.
0
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
https://www.zacks.com/stock/news/2216537/analysts-estimate-bristol-myers-squibb-bmy-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2216537
Jan 26, 2024 - Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store?
https://www.zacks.com/stock/news/2215142/novartis-nvs-to-report-q4-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2215142
Jan 24, 2024 - Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
0
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth
https://www.zacks.com/stock/news/2215035/gsk-gsk-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2215035
Jan 24, 2024 - Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0